CSBio CSBio

X
[{"orgOrder":0,"company":"Kandy Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$875.0 million","upfrontCash":"$425.0 million","newsHeadline":"Bayer to Acquire UK-Based Biotech KaNDy Therapeutics Ltd.","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kandy Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            KaNDy Therapeutics Ltd. recently completed the Phase IIb with NT-814, a first in class, non-hormonal, once-daily, oral neurokinin-1,3 receptor antagonist, publishing positive data for the treatment of frequent symptoms of the menopause, hot flashes and night sweats.

            Lead Product(s): Elinzanetant

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: NT-814

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bayer AG

            Deal Size: $875.0 million Upfront Cash: $425.0 million

            Deal Type: Acquisition August 11, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY